Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections
References (22)
- et al.
Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships
Genomics
(1996) - et al.
Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue
Am J Pathol
(2001) - et al.
Real-time quantitative reverse transcription-PCR assay for renal cell carcinoma-associated antigen G250
Clin Chim Acta
(2002) - et al.
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation
Am J Pathol
(1998) - et al.
Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts
Gastroenterology
(1997) - et al.
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
Int J Cancer
(2000) - et al.
Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion
Br J Cancer
(2000) - et al.
The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma
Semin Oncol
(1995) - et al.
Phase I/II radioimmu-notherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
Clin Cancer Res
(1998) - et al.
The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts
Cancer
(1997)
Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts
Int J Cancer
Cited by (22)
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography
2016, Journal of UrologyCitation Excerpt :Antibodies against CAIX (antigen G250) can be used for immunohistochemical staining and for immuno-PET. CAIX expression has been observed in 95% of clear cell carcinomas but not in normal renal tissue, benign tumors or other types of renal malignancies.10 A chimeric mouse-human antibody (cG250-girentuximab) has been constructed, allowing multiple administrations in the same patient without provoking an immune response.11
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy
2010, European UrologyCitation Excerpt :Furthermore, alveolar and/or tubular growth patterns demonstrated high (94–99%) CAIX expression. Papillary, solid, and cystic growth patterns were characterised by significantly lower (14–60%) CAIX expression [12]. In various other tumours, immunohistochemical analyses revealed high levels of CAIX expression: carcinomas of the uterine cervix, oesophagus, lung, breast, brain, and vulva also express CAIX, albeit all very heterogeneously [13–20].